Abstract 2136P
Background
Prostate cancer (PC) patients face treatment-related sequelae that affect their health and quality of life. The PCSC Program was created in 2013 and is located in the Vancouver Prostate Centre’s urology clinic. It is a clinical, educational, and research-based program that addresses challenges experienced by PC patients from the time of diagnosis onward. The program consists of 8 “modules” listed in the table.
Methods
We describe the operational details of the PCSC Program and its metrics.
Results
A Medical Director and Program Manager set the mission, oversee the day-to-day operations, and hire and manage the allied health clinicians and support staff. Office/clinic space is rotated during the week to accommodate a sexual health RN (1.4 FTE), 2 pelvic floor physiotherapists, a nurse practitioner, a registered dietitian, a clinical exercise physiologist (all 0.2 FTE), and a clinical counsellor (0.4 FTE). As of 05/2023, 3351 pts have registered for this no-cost program (Table). In 4/2020, the real-time group education sessions and clinic appointments transitioned from in-person to a hybrid with virtual options enabling the participation of patients from throughout British Columbia.
Table: 2136P
Attendance at PCSC modules for 3351 registrants from 2013 to May 2023
Modules | Attendees, n | Group education*, n (# sessions) | Clinic appointments, n (# appointments) |
Introduction to PC and primary treatment options | 945 | 955 (159) | not applicable |
Managing sexual function and intimacy | 1745 | 844 (122) | 1519 (6109) |
Management of side effects of ADT | 443 | 376 (25) | 212 (313) |
Pelvic floor physiotherapy for incontinence | 1304 | 910 (97) | 594 (2382) |
Counselling | 444 | not applicable | 444 (1629) |
Metastatic disease management | 85 | 87 (30) | not applicable |
Nutrition | 742 | 195 (31) | 361 (593) |
Exercise | 826 | 455 (70) | 674 (2167) |
*Some attendees attended the group education sessions more than once.
Conclusions
The need for PC supportive care is well recognized but may be challenging to offer when the services are fragmented and time-consuming for clinicians or staff to arrange. All modules offered by the PCSC Program can be accessed with one registration. It is convenient for patients because it is housed in one location, which also facilitates communication across disciplines. We attribute the success of our program to this model and our team approach to the individual patient’s needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Prostate Cancer Supportive Care Program.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07